For years, investors were told that broad diversification is the closest thing to a free lunch in markets. Today, many are doing exactly the opposite: paying up for trend-driven, highly concentrated products that are designed to magnify short-term price movements in individual stocks, often with limited awareness of the risks embedded in these products.
Nowhere is this shift more evident than in the explosive growth of single-stock leveraged products in Hong Kong. The CSOP SK Hynix Daily (2X) Leveraged Product, launched in October 2025, rocketed to the top of the Hong Kong ETF market by asset size within months of its launch, briefly surpassing the Tracker Fund of Hong Kong on June 22, 2026 (Exhibit 1). The latter tracks the Hang Seng Index and has been in existence for nearly three decades.
Exhibit 1: CSOP SK Hynix Daily (2X) Leveraged Product’s Rapid Rise in Assets
According to its prospectus, CSOP SK Hynix Daily (2X) Leveraged Product seeks to deliver, before fees and expenses, twice (2x) the daily performance of SK Hynix Inc (000660) through the use of financial derivative instruments, such as swaps and options. Its rapid asset accumulation has closely followed the strong rally in SK Hynix shares – a South Korean company which specializes in memory chips manufacturing - which have risen fivefold over the past six months thanks to the ongoing AI rally, highlighting the extent to which investor demand has been driven by momentum in the underlying stock.
In general, leveraged and inverse products, whether tracking a single stock or an index, have been a key driver of inflows among Hong Kong-listed ETFs in recent quarters. For instance, in the first quarter of 2026, these products accounted for nearly a third of the HKD 62.2 billion that flowed into the market. For a deeper look at these trends, see Morningstar’s APAC ETF Flows Q1 2026 report. Exhibit 2 shows the five largest leverage and inverse products by assets listed in Hong Kong.
Exhibit 2: Leveraged and Inverse Products Carry High Fees and Significant Downside Risk
The Risks Beyond the Headline Appeal
Amid the sharp rally in technology and AI-related stocks, the headline returns of leveraged products are understandably tempting. They offer investors an easy way to double down on their bets, something that would otherwise be difficult to achieve. But leverage is a double-edged sword and can amplify losses just as sharply when the tide turns.
Meanwhile, inverse products – which aims to profit from declines in its underlying investment and can be used as a hedging tool – suffer when the underlying investment moves up and inherently implies market-timing risks. Indeed, it has been challenging for the CSOP Hang Seng Index Daily (-2x) Inverse Product, as reflected in its poor one-year and three-year returns (Exhibit 2) while the Hang Seng Index has been up during these periods.
Beyond that, leveraged and inverse products are expensive to hold: costs associated with leverage and high fees can meaningfully drag on returns over the long term compared to more traditional ETFs or diversified open-end funds. Overall, these are products that are poorly suited for most investors, and we highlight the key risks that investors should be aware of before considering them.
Risks and Complexities that Investors Should Be Aware Of
By design, single-stock leveraged and inverse products are inherently more complex and carry risks that differ meaningfully from those of traditional, unleveraged ETFs tracking diversified indexes. While some of these risks may be implied in the product names, the underlying mechanics are often far more intricate than they appear, leading to potential leakages or return deviations relative to the product’s stated target exposures.
(1) Concentration risk
A single-stock leveraged or inverse product seeks to deliver leveraged or inverse returns tied to one underlying stock. In the case of the CSOP SK Hynix Daily (2X) Leveraged Product, exposure is linked to the share-price performance of SK Hynix (000660, listed in South Korea). As a result, the product is concentrated in a single stock, rather than a broad portfolio of securities typically held by a traditional ETF.
(2) Leverage amplifies both risk and return
While the word “leveraged” is prominently featured in the product name itself, it is worth reminding investors that this translates to amplified exposures to the underlying stock/index– both in terms of risk and return, and the drawdown in certain periods can be extreme. For example, the CSOP SK Hynix Daily (2X) Leveraged Product experienced a decline of 52% during March 2026 alone. Meanwhile, inverse products have the objective to deliver the inverse (some with multiples, e.g. -2x) returns of their underlying exposures, altering the risk and return profile entirely.
(3) Volatility drag can erode returns over time
The word “daily” in CSOP SK Hynix Daily (2X) Leveraged Product is critical. Leveraged and inverse products in Hong Kong typically seek to deliver 2x, -1x or -2x the daily return of the underlying index, before fees and expenses. Over periods longer than one day, however, their returns may differ meaningfully from the stated multiple of the underlying security’s cumulative return. This effect is commonly known as “volatility drag.”
The following example illustrates how volatility can erode returns in leveraged or inverse single-stock products (Exhibit 3). Over longer periods, the reference stock generally needs to rise consistently for returns to meet, or exceed, the stated leverage. A more volatile, zigzagging path can make it difficult for these products to compound to the stated multiple, even though achieving that multiple over longer holding periods is not their stated objective.
Exhibit 3: Illustration of Volatility Drag on Leveraged/Inverse Products
(4) Fees are high
As illustrated in Exhibit 2, the five largest leveraged/inverse products levy ongoing charges in the range of 1.05% to 2.00% per annum. This is multitudes more expensive than those of traditional, non-leveraged/inverse index tracking ETFs. By comparison, the Tracker Fund of Hong Kong charges just 0.06% per annum. The higher fees on these leveraged/inverse products create an additional drag on performance, further detracting from the products’ ability to deliver their stated multiple of the underlying stock or index returns.
In addition to the ongoing charges, to obtain the leveraged/inverse exposures, the products utilize financial derivative instruments which incur costs which are borne by the products and reflected in the products’ NAV, hence impacting the products’ tracking difference and tracking error. These costs are difficult to predict as they vary with the market conditions. These costs can increase significantly in extreme conditions and might at times, on the other hand, be “negative”, meaning a positive impact on the products’ tracking difference.
To illustrate the magnitude of these costs, here’s an abstract from the Product Key Facts of the CSOP SK Hynix Daily (2X) Leveraged Product and the daily tracking difference of the product (that is, the daily deviation of the product’s return and the 2x daily performance of the underlying stock) so far in June 2026, which worsen to more than -1% (daily) in multiple days:
“The costs from swaps and options are expected to range from 7.50% to 20.00% per annum of the swap and option notional amount, i.e. from 15.00% to 40.00% per annum of the Product’s NAV where the Product invests up to 49% of its NAV in options.”
Exhibit 4: Daily Tracking Difference of CSOP SK Hynix Daily (2X) Leveraged Product in June 2026
(5) Market trading aspects to be considered
Single-stock leveraged/inverse products trade on the stock exchange and may change hands at a premium or discount to their prevailing NAV. These premiums or discounts can arise from market supply and demand dynamics, trading conditions, and timing differences, and may fluctuate throughout the trading day. As a result, they can affect investor returns when shares are bought or sold in the secondary market. Exhibit 5 shows the day-end premium/discount levels of the CSOP SK Hynix Daily (2X) Leveraged Product so far in June 2026, with premium levels shooting up to as high as 12% during the period.
Exhibit 5 CSOP SK Hynix Daily (2X) Leveraged Product’s Premium/Discount Can Vary Significantly
Other trading aspects include investors’ transaction costs and bid/ask spreads, etc. can all have an impact on investor returns.
(6) Putting all these together - watch for return leakages
To further illustrate the above risks and complexities, in particular, when holding leveraged/inverse products over longer periods, as well as the impact from fees and transaction costs, which can lead to leakages on returns, we look at the performance of a pair of leveraged (2x) and inverse (-2x) products with the Hang Seng Index as the underlying exposure. This example shows how performance can deviate from the targeted exposures over time. As shown in Exhibit 6, from their common inception date, through to 22 June 2026, both the leveraged (2x) and inverse (-2x) products underperformed the Hang Seng Index. Over the period, the 2x leveraged product returned -47%, the -2x inverse product returned -73%, while the Hang Seng Index (price return) declined by 13%.
Exhibit 6: Despite Opposite Exposures, Both Products Trailed their Underlying Hang Seng Index
Buyer Beware
For most investors, leveraged and inverse products are generally not appropriate as buy-and-hold investments. They tend to be better suited to active traders who understand how these products work and use them for short-term trading or hedging purposes.
Looking ahead, the Hong Kong Securities and Futures Commission (SFC) revised its “Circular on Listed Structured Funds” on 6 June 2026 to broaden the scope of single-stock leveraged and inverse products to reference highly liquid Hong Kong-listed mega-cap stocks. Previously, only overseas-listed stocks were eligible. As more single-stock leveraged and inverse ETFs are expected to come to market, investors should exercise caution and develop a thorough understanding of these products before buying them.
